Q4 2025 · 13F-HR
JOHNSON & JOHNSON (JNJ)holdings as filed
Filed 2026-02-13 · accession 0000904454-26-000111
$554.6M
Reported value
17
Positions
2025-12-31
Period end
The Brief · JOHNSON & JOHNSON (JNJ) · Q4 2025
AI · grounded in 13F
JOHNSON & JOHNSON (JNJ) established a new position in Protagonist Therapeutics Inc. PTGX valued at $213.9M. The fund also initiated a $130M stake in Nanobiotix S.A. NBTX. Additional new positions include Rapport Therapeutics, Inc. RAPP at $54.1M and MeiraGTx Holdings plc MGTX at $52.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74366E102 | PTGX | Protagonist Therapeutics Inc. | $213.9M | 38.6% | 2,449,183 | Common | SHARED |
| 63009J107 | NBTX | Nanobiotix S.A. | $130.0M | 23.4% | 5,623,816 | Common | SHARED |
| 75383L102 | RAPP | Rapport Therapeutics, Inc. | $54.1M | 9.76% | 1,784,517 | Common | SHARED |
| G59665102 | MGTX | MeiraGTx Holdings plc | $52.8M | 9.52% | 6,641,064 | Common | SHARED |
| 126638105 | CVRX | CVRx, Inc. | $28.6M | 5.15% | 4,024,861 | Common | SHARED |
| 21217B100 | CTNM | Contineum Therapeutics Inc. | $22.6M | 4.08% | 1,979,173 | Common | SHARED |
| 52490G102 | LEGN | Legend Biotech Corporation | $17.7M | 3.19% | 814,586 | Common | SHARED |
| 98401F105 | XNCR | Xencor, Inc. | $11.5M | 2.06% | 748,062 | Common | SHARED |
| 74276L105 | PRCT | Procept BioRobotics Corporation | $11.3M | 2.03% | 357,939 | Common | SHARED |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $3.3M | 0.60% | 3,379,064 | Common | SHARED |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $3.3M | 0.60% | 1,849,445 | Common | SHARED |
| 75120L100 | RLYB | Rallybio Corporation | $2.5M | 0.45% | 3,636,363 | Common | SHARED |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $1.3M | 0.23% | 41,165 | Common | SHARED |
| 929033207 | VOR | Vor Biopharma, Inc. | $702,815 | 0.13% | 53,732 | Common | SHARED |
| M70700105 | NNOX | Nano-X Imaging Ltd. | $444,786 | 0.08% | 158,852 | Common | SHARED |
| 34385P108 | LAB | Standard BioTools, Inc. | $399,318 | 0.07% | 311,967 | Common | SHARED |
| 007002207 | ACET | Adicet Bio, Inc. | $191,803 | 0.03% | 22,779 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.